CRSP - CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
As of May 15, 2026: spot at $48.77, ATM IV 53.9%, max pain $50.00, net GEX -$465.9K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $5.09B
- Beta
- 1.74
- 52-Week Range
- 34.87-78.48
- CEO
- Samarth Kulkarni
- Employees
- 393
- IPO Date
- Oct 19, 2016
- Exchange
- NASDAQ
What CRSP Looks Like to Options Traders Today
IV rank of 12.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$465.9K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (0.022) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The CRSP overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked CRSP overview questions
- What is CRSP?
- CRSP is the ticker symbol for CRISPR Therapeutics AG, a listed security. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. Listed on NASDAQ. CRSP is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the CRSP options snapshot look like today?
- As of May 15, 2026, the CRSP options snapshot shows spot at $48.77, ATM IV 53.9%, IV rank 12.8%, max pain $50.00, net GEX -$465.9K, expected move 15.45%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are CRSP's key statistics?
- CRISPR Therapeutics AG (CRSP) carries a market capitalization of $5.09B, beta of 1.74 relative to the broader market, 52-week range of 34.87-78.48. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does CRSP belong to?
- CRISPR Therapeutics AG operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare CRSP's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the CRSP data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).